Multiple Myeloma

In MMY1001, median PFS was 14.1 months and median OS was 21.1 months in patients with lenalidomide-refractory myeloma treated with daratumumab/carfilzomib.

A once-weekly regimen of carfilzomib plus dexamethasone improved response and delayed progression better than a twice-weekly regimen in R/R MM.

OPTIMISMM is the only phase III trial to show a significant PFS benefit in R/R MM patients with prior exposure to lenalidomide.

Therapy with CAR T cells may benefit patients with highly refractory multiple myeloma, said U Penn’s Adam Cohen at ASCO 2018.

Risk stratification is leading to increasing numbers of new molecular targets in multiple myeloma.

A UK team found multiple targets of non-coding mutations, highlighting the importance of broadening the search for cancer drivers into the regulatory genome.

Investigators concluded further investigations are warranted in elderly patients with either stable or responsive disease after bortezomib induction therapy.

Challenge yourself with our latest quiz, covering management considerations in the treatment of patients with transplant-ineligible myeloma.

Take our latest quiz to learn about differences in MM incidence, complications, and treatment among men, women, and various racial and ethnic groups.

Three year OS was significantly worse compared with the general population, with a persistent risk for relapse.

A large prospective analysis of three large cohorts found a positive link between risk for myeloma and cumulative average young adult and adult BMI.

How much do you understand about evaluating prognosis and choosing treatment for patients with myeloma? Take our latest quiz to find out.

The oral therapy combination of ixazomib, pomalidomide, and dexamethasone was effective and well-tolerated in patients with myeloma that had relapsed or was refractory to lenalidomide.

Nearly 80% of R/R myeloma patients with severe renal impairment requiring hemodialysis achieved disease control with this treatment combination.

Do you know what dose of carfilzomib is associated with an increased incidence of cardiovascular events in multiple myeloma patients? How about the estimated incidence of new myeloma cases in 2018? Test your knowledge in our latest quiz.

The FDA has approved denosumab (Xgeva) for the prevention of skeletal-related events in patients with bone metastases and multiple myeloma.

Is the use of bisphosphonates in patients with multiple myeloma associated with improved progression-free or overall survival? Is hypertension a risk factor for carfilzomib-related cardiopulmonary toxicities? Test your knowledge in our latest quiz.

Among patients with relapsed or refractory multiple myeloma, adding carfilzomib to lenalidomide and dexamethasone improves overall survival compared with lenalidomide and dexamethasone alone.

Treatment with carfilzomib for multiple myeloma was associated with increased incidence of cardiovascular adverse events, especially with higher doses.

Continuous treatment with lenalidomide/dexamethasone significantly improved survival in patients with transplant-ineligible newly diagnosed multiple myeloma.

MMG49 has been identified as a monoclonal antibody that can be targeted using CAR T-cell therapy for patients with multiple myeloma.

An investigational antibody-drug conjugate that targets a key B-cell maturation antigen, offers “deep and durable” responses to some patients with relapsed/refractory multiple myeloma, suggest preliminary findings from the expansion part of the phase I DREAMM-1 trial.

Adding daratumumab to either of two standard-of-care treatment regimens induces rapid, deep, and durable responses and improves progression-free survival in patients with relapsed/refractory multiple myeloma, confirm updated findings from the open-label phase III POLLUX and CASTOR trials.

A single treatment with a second-generation CAR T-cell treatment elicited an overall response rate of 94% in a small study of patients with heavily pretreated multiple myeloma, according to the results of a phase I study presented at the ASH Annual Meeting.

Continuous lenalidomide therapy improves outcomes among patients with newly diagnosed myeloma who are not autologous stem cell transplant candidates, according to findings from a large phase III clinical trial.

The 4-year overall survival rate is 82.3% among multiple myeloma patients eligible for autologous stem cell transplantation, according to a retrospective study.

Do you know when to switch treatment combinations or stop certain treatments altogether in the management of patients with multiple myeloma? Take part in a series of case scenarios and see if you can pick the correct course of action for each in our latest quiz.

Elevated pre-transplant C-reactive protein was associated with worse overall survival in patients who underwent autologous stem cell transplantation for multiple myeloma, particularly in those who had transplant more than 12 months after diagnosis.

The BCL-2 inhibitor venetoclax had an acceptable safety profile and showed evidence of activity in patients with relapsed/refractory multiple myeloma.

Are you up to date on the NCCN guidelines for multiple myeloma? And do you know the best way to treat a 66-year-old patient with a lytic rib mass that shows infiltration by kappa light chain restricted plasma cells on core needle biopsy? Test your knowledge in our latest quiz.